Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 02, 2024

BUY
$48.48 - $57.85 $218,160 - $260,325
4,500 New
4,500 $230,000
Q1 2023

May 02, 2023

SELL
$65.71 - $74.53 $91,993 - $104,342
-1,400 Reduced 11.11%
11,200 $776,000
Q4 2022

Jan 03, 2023

BUY
$68.48 - $81.09 $862,848 - $1.02 Million
12,600 New
12,600 $33,000
Q1 2022

Apr 14, 2022

BUY
$61.48 - $73.72 $1.12 Million - $1.34 Million
18,200 New
18,200 $3,000
Q1 2021

Apr 29, 2021

SELL
$59.34 - $66.74 $1.11 Million - $1.25 Million
-18,700 Closed
0 $0
Q4 2020

Jan 13, 2021

BUY
$57.74 - $65.43 $1.08 Million - $1.22 Million
18,700 New
18,700 $37,000
Q3 2020

Oct 28, 2020

SELL
$57.43 - $63.64 $758,076 - $840,048
-13,200 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $109,640 - $128,180
2,000 Added 17.86%
13,200 $32,000
Q1 2020

Apr 09, 2020

SELL
$46.4 - $67.43 $1.87 Million - $2.72 Million
-40,400 Reduced 78.29%
11,200 $13,000
Q4 2019

Jan 06, 2020

BUY
$49.21 - $64.19 $1.47 Million - $1.91 Million
29,800 Added 136.7%
51,600 $5,000
Q3 2019

Oct 03, 2019

SELL
$42.77 - $50.71 $620,165 - $735,295
-14,500 Reduced 39.94%
21,800 $30,000
Q2 2019

Jul 10, 2019

SELL
$44.62 - $49.34 $1.64 Million - $1.81 Million
-36,700 Reduced 50.27%
36,300 $117,000
Q1 2019

Apr 08, 2019

BUY
$45.12 - $53.8 $2.28 Million - $2.72 Million
50,500 Added 224.44%
73,000 $92,000
Q4 2018

Jan 03, 2019

BUY
$48.76 - $63.23 $390,080 - $505,840
8,000 Added 55.17%
22,500 $109,000
Q3 2018

Oct 04, 2018

BUY
$55.19 - $62.25 $248,355 - $280,125
4,500 Added 45.0%
14,500 $24,000
Q2 2018

Jul 06, 2018

BUY
$50.53 - $62.98 $505,300 - $629,800
10,000 New
10,000 $38,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Xr Securities LLC Portfolio

Follow Xr Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xr Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Xr Securities LLC with notifications on news.